Kumud Tripathy
Medical Oncology · Bryan, TXNPI 1811949407
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 66 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $543 and has fallen 84.4% since, to $85 in 2024. That places this record below the midpoint for medical oncology clinicians in TX, where the typical reported total is $4,372.
Across 66 payments — averaging $28.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$309
- Johnson & Johnson$258
- Myriad Genetic Laboratories, Inc.$129
- Incyte Corporation$125
- Jazz Pharmaceuticals Inc.$121
- Merck$88
- plus $819 from 27 others
Across 6 payments — averaging $5921.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$36K
What the payments were for
- Food & beverage$1,80598%
- Education$452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 6 | $309 |
| Johnson & Johnson | 12 | $258 |
| Myriad Genetic Laboratories, Inc. | 1 | $129 |
| Incyte Corporation | 1 | $125 |
| Jazz Pharmaceuticals Inc. | 2 | $121 |
| Merck | 3 | $88 |
| Tempus AI, Inc | 3 | $85 |
| Bristol Myers Squibb | 4 | $73 |
| Lilly USA, LLC | 3 | $62 |
| AstraZeneca | 3 | $51 |
| Regeneron Healthcare Solutions, Inc. | 1 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Gilead | 2 | $32 |
| Boehringer Ingelheim | 2 | $31 |
| Ipsen Biopharmaceuticals, Inc | 1 | $30 |
| Deciphera Pharmaceuticals Inc. | 1 | $30 |
| Organon | 4 | $29 |
| Spectrum Pharmaceuticals Inc. | 1 | $28 |
| Tersera Therapeutics LLC | 1 | $26 |
| Dendreon Pharmaceuticals LLC | 1 | $25 |
| Adaptive Biotechnologies Corporation | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Tesaro, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| Seagen Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $21 |
| GSK | 1 | $19 |
| Sanofi | 1 | $19 |
| Pfizer | 1 | $18 |
| Exelixis Inc. | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $14 |
| Bayer | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- myChoice CDx$129
- JAKAFI$125
- XGEVA$123
- Vectibix$122
How this compares
$1,849 in reported general payments places this provider in the 30th percentile of 495 medical oncology providers in Texas.
Other medical oncology in Bryan
- Moshe LevyDallas$5.1M
- Suresh RatnamMcAllen$3M
- Roy HerbstHouston$1.9M
- Andrew WhiteleyDallas$1.7M
- Eric NadlerDallas$1.6M
- Vijay GunugantiSan Antonio$1.5M
- Sue EckhardtAustin$1.5M
- Joyce O'ShaughnessyDallas$1.3M
- Ronan KellyDallas$1.1M
- Maen AbdelrahimHouston$999K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.